Israels Scientific Ethos Driving Pharma Industry Value Beyond $2.3 Billion by 2020
Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion by 2020, driven by medical technology advances, high R&D expenditure and a robust economy, according to research and consulting firm GlobalData.
Furthermore, the company’s latest report* states that this rise, which represents a modest compound annual growth rate (CAGR) of 2.8%, will occur in a country with high levels of generic production and pharmaceutical exports.
Israel is home to Teva Pharmaceuticals, which is one of the world’s largest generics manufacturers and exporters. The country’s entire pharmaceutical exports were worth approximately $7.1 billion in 2013, more than four times the value of its imports, which was just over $1.7 billion.
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “Israel is one of the major healthcare markets in the Middle East.
“Pharmaceuticals represent the largest and most established sector of the Israeli life science industry, with a total of 76 companies, of which 22% are involved in drug discovery and 17% in drug delivery.”
The director adds that this commitment to scientific development is fortified by a highly skilled population, with Invest in Israel highlighting that the country is ranked second in the world for percentage of engineers and scientists in the workforce.
Owide continues: “Approximately 24% of Israel’s workers hold university degrees, placing it third among the industrialised countries, after the US and Netherlands.
“Israel’s pharmaceutical sector is supported by a network of recognised academic and research institutes, R&D facilities, and well-developed medical centers. Indeed, Israeli research expertise and clinical advances have led to the development of blockbuster drugs and promising treatments.”
Such products include Johnson and Johnson’s Doxil for ovarian cancer, which was originally developed at the Hadassah Medical Center, as well as Teva Pharmaceuticals and the Weizmann Institute’s Copaxone for multiple sclerosis, and Novartis’ Exelon for Alzheimer’s disease, originating from research conducted at the Hebrew University.
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape — Israel
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance